Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:INBP NASDAQ:SNPX NASDAQ:TSBX OTCMKTS:VGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBPIntegrated BioPharma$0.27-4.9%$0.31$0.16▼$0.42$8.67M0.89,410 shs1,004 shsSNPXSynaptogenix$9.56+14.6%$6.73$1.84▼$7.85$13.29M1.08250,819 shs467,085 shsTSBXTurnstone Biologics$0.36$0.36$0.29▼$2.42$8.22M1.36142,319 shsN/AVGLSVG Life Sciences$0.00$0.00$0.00▼$0.00$2.11M1.673.91 million shs929,000 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBPIntegrated BioPharma-5.72%+3.70%-12.50%-15.15%+62.79%SNPXSynaptogenix+12.86%+41.60%-7.23%+275.68%+120.05%TSBXTurnstone Biologics0.00%-0.84%-1.63%+2.16%-84.22%VGLSVG Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINBPIntegrated BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/AN/AN/AN/ATSBXTurnstone Biologics2.8019 of 5 stars2.85.00.00.00.92.51.3VGLSVG Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBPIntegrated BioPharma 0.00N/AN/AN/ASNPXSynaptogenix 0.00N/AN/AN/ATSBXTurnstone Biologics 1.50Reduce$0.4526.76% UpsideVGLSVG Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBPIntegrated BioPharma$50.32M0.16$0.04 per share6.32$0.64 per share0.42SNPXSynaptogenixN/AN/AN/AN/A$4.33 per shareN/ATSBXTurnstone Biologics$19.31M0.43N/AN/A$0.64 per share0.55VGLSVG Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBPIntegrated BioPharma$110K$0.046.66∞N/A2.37%6.36%4.84%9/18/2025 (Estimated)SNPXSynaptogenix-$12.77M-$10.08N/A∞N/AN/A-115.28%-58.31%N/ATSBXTurnstone Biologics-$70.84M-$2.05N/AN/AN/AN/A-171.86%-128.13%N/AVGLSVG Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VGLS, INBP, TSBX, and SNPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025TSBXTurnstone Biologics-$0.16-$0.24-$0.08-$0.24N/AN/A5/15/2025Q1 2025SNPXSynaptogenixN/A$0.04N/A$0.04N/AN/A5/14/2025Q3 2025INBPIntegrated BioPharmaN/A$0.02N/A$0.02N/A$13.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINBPIntegrated BioPharmaN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBPIntegrated BioPharmaN/A3.721.70SNPXSynaptogenixN/A72.5972.59TSBXTurnstone BiologicsN/A3.333.70VGLSVG Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBPIntegrated BioPharma25.25%SNPXSynaptogenix10.34%TSBXTurnstone Biologics52.51%VGLSVG Life SciencesN/AInsider OwnershipCompanyInsider OwnershipINBPIntegrated BioPharma67.20%SNPXSynaptogenix2.73%TSBXTurnstone Biologics32.10%VGLSVG Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBPIntegrated BioPharma15030.98 million10.16 millionNot OptionableSNPXSynaptogenix41.39 million1.35 millionNot OptionableTSBXTurnstone Biologics8223.14 million15.71 millionNot OptionableVGLSVG Life Sciences121.10 billionN/ANot OptionableVGLS, INBP, TSBX, and SNPX HeadlinesRecent News About These CompaniesVGLS VG Life Sciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comCamfil USA Unveils Absolute® VG: Advanced V-Bank HEPA Filters with Gasket and Gel SealsOctober 31, 2024 | markets.businessinsider.comVG Life Sciences Inc.September 14, 2024 | barrons.comVG Life Sciences, Inc. Increases Authorized SharesAugust 16, 2024 | br.advfn.comVG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10August 16, 2024 | br.advfn.comVG Life Sciences Inc. (VGLS)March 1, 2024 | finance.yahoo.comVG Life Sciences Stock (OTC:VGLS), Insider Trading ActivityFebruary 27, 2024 | benzinga.comEmerging from a Recent Pullback, Life Sciences Has a PulseJanuary 18, 2024 | globest.comGVG Life Sciences Inc VGLSNovember 16, 2023 | morningstar.comMReport warns of 'oversupply' of life sciences real estateSeptember 17, 2023 | bizjournals.comVGLS VG Life Sciences Inc.February 16, 2023 | seekingalpha.comThe best Life is Strange game is on PlayStation Plus right now – and it’s not what you thinkJanuary 26, 2023 | vg247.comVNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVGLS, INBP, TSBX, and SNPX Company DescriptionsIntegrated BioPharma OTCMKTS:INBP$0.27 -0.01 (-4.89%) As of 01:55 PM EasternIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.Synaptogenix NASDAQ:SNPX$9.56 +1.22 (+14.63%) As of 08/13/2025Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.Turnstone Biologics NASDAQ:TSBX$0.36 0.00 (0.00%) As of 08/11/2025Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.VG Life Sciences OTCMKTS:VGLS$0.0001 0.00 (0.00%) As of 12:31 PM EasternVG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access